Top 5 health benefits trends of 2023
COVID-19 pushed an industry that was slowly digitizing to move quickly to meet the rapidly evolving needs of its employers and plan members.
Read article
Insurers
Get in depth knowledge of the group health benefits industry in Canada, and learn from our experts on how you can best design employee benefits plans, while ensuring plan costs remain sustainable.
-
-
5 levers to slow the rise of pharmacy benefits costs
Drug costs are on the rise, but there are ways to combat this. Check out our five levers to slowing the growth of pharmacy benefits costs.
Read article
-
Mental health in the workplace - a prime focus for employers
Mental health indicators are in decline lately, a function of the recent economic downturn and three years of a global pandemic. Many employees are feeling isolated, anxious and unproductive.
Read article
-
What you need to know about drug data trends in 2022.
For the second year in a row, fewer claims were made for prescription drugs while the average eligible amounts per insured and per claim increased.
Read article
-
TELUS Health Annual Conference 2022
Presentations from May 10 & 17, 2022 events "Retrospective 2021: Data trends and national benchmarks" with Shawn O’Brien, Principal, Data Enablement, TELUS Health
Read article
-
Don’t miss it: The 2022 Drug Data Trends & National Benchmarks report.
Year two of the COVID-19 pandemic saw the continuation of lower rates of prescribing for high-volume drugs such as antibiotics.
Read article
-
What’s your plan to help employees manage chronic conditions?
Explore some of the impacts of limited diagnostic and treatment services for chronic conditions and how to help minimize costs and support improved outcomes.
Read article
-
2022 category watch: Impact of the pandemic
TELUS Health’s 2022 Category Watch examines the impact of the COVID-19 pandemic on drug utilization for the treatment of four health issues: depression, pain, substance use disorder and weight...
Read article
-
Employers bracing for rising cancer claims
The pandemic created delays in testing, diagnosis and treatment of serious acute and chronic illnesses, including cancer that could reverberate for years.
Read article
-
What new drugs are poised to have the biggest impact on plan costs?
A look at approved and likely soon-to-be-approved high-cost therapies for conditions such as Alzheimer’s disease, macular degeneration and more.
Read article
-
Disability management post-COVID: What employers should know
Post-pandemic, many employes are setting up new ways of working and new health and safety protocols while anticipating a sharp rise in disability claims.
Read article
-
The private payer’s perspective: Drug trends
The COVID-19 pandemic has alteried how medications are prescribed and how innovative therapies emerge, leading to changes in the Canadian pharmaceutical market.
Read article
-
Drug plans decoded: Biosimilars Part 4
Biosimilars in Canada: what plan sponsors can do. For plan sponsors that want to take advantage of the savings available through biosimilar biologics, several options are available. Since the...
Read article
-
Diabetes and Canadian employers
Diabetes is a silent pandemic that is costing employers and insurers millions of dollars a year in lost productivity, disability claims and drug spending.
Read article
-
Drug plans decoded: Biosimilars Part 3
Public plans drive adoption of biosimilars So far, four provinces in Canada —British Columbia, Alberta, Quebec and New Brunswick—have adopted biosimilar transitioning or switching strategies, in...
Read article
-
Mental health, virtual care rise to surface: Highlights from the 2021 Benefits Canada Healthcare Survey
Employee health has declined over the past year, while the utilization of employee assistance programs, mental health paramedical services and prescription drugs have increased, reports the 2021...
Read article
-
Can technology create great plan member experiences?
Managing group health benefits costs, digitizing benefits delivery and data insights are key areas of focus for plan sponsors and advisors. However, our research shows another top priority going...
Read article
-
Supporting caregiver employees
The pandemic shone a bright light on the resilience of Canada’s healthcare system, and on the challenges still to address in our long-term care and seniors’ health services.
Read article
-
Drug plans decoded: Biosimilars Part 2
How Canada compares on biosimilars. Canada lags many countries when it comes to the uptake of biosimilar biologics, as determined by availability, prescribing patterns and policies for coverage...
Read article
-
Drug plans decoded: Biosimilars Part 1
Biosimilars 101: what you need to know. Four provinces so far have implemented or are implementing mandatory switching policies to boost the utilization of biosimilar drugs. B.C. and Alberta...
Read article
-
Loading more...
